The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, ...

A 74-year-old woman develops haemolytic anaemia and stress cardiomyopathy after a tick bite, highlighting a rare cardiac complication of babesiosis.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Researchers at the German Centre for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of heart failure that has so far been difficult to treat. Prof. Johannes Backs, ...

Patients with overweight or obesity and heart failure with preserved ejection fraction that have unintentional weight loss have worse outcomes.

An artificial intelligence model developed by Mayo Clinic and Ultromics accurately screens for cardiac amyloidosis using a ...

CVRx (Nasdaq:CVRX) announced today that CMS proposed to keep its Barostim implant procedure within a certain payment class.

The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...

A new study shows that people with a type of heart failure called HFpEF (heart failure with preserved ejection fraction) are ...